Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBKX3C)

• Drug Name: VESNARINONE Drug Info
• Synonyms: vesnarinone; 81840-15-5; Arkin-Z; Piteranometozine; OPC-8212; Arkin; Vesnarinonum [Latin]; Vesnarinona [Spanish]; UNII-5COW40EV8M; OPC 8212; Vesnarinone [USAN:INN:JAN]; CCRIS 1451; DRG-0210; BRN 5644229; 5COW40EV8M; CHEMBL17423; 6-(4-(3,4-Dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1H)-; 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine; 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one; 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1H)-quinolinone

Indication

Disease Entry	ICD 11	Status	REF
Cardiac failure	BD10-BD13	Approved	[1]

• Cross-matching ID:
  PubChem CID: 5663
  ChEBI ID: CHEBI:31237
  CAS Number: CAS 81840-15-5
  TTD Drug ID: DMBKX3C

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated potassium channel Kv11.1 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[5]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[6]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[7]
ABT-229	DMN3S1B	Pain	MG30-MG3Z	Phase 2	[8]
ISOQUINE	DMR17YI	Malaria	1F40-1F45	Phase 1	[9]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[10]
Isoindoline derivative 5	DMIUTQW	N. A.	N. A.	Patented	[11]
Isoindoline derivative 3	DM2MYL9	N. A.	N. A.	Patented	[11]
Isoindoline derivative 4	DMP1NKI	N. A.	N. A.	Patented	[11]
Isoindoline derivative 2	DMTE0S3	N. A.	N. A.	Patented	[11]

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[12]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[13]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[14]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[15]
BEMORADAN	DMUL6GY	Heart failure	BD10-BD13	Phase 2	[1]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[16]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[1]
IMAZODAN	DMWTFO3	N. A.	N. A.	Terminated	[17]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[18]
BMY-20844	DMDPJ8M	N. A.	N. A.	Terminated	[19]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[20]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[21]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[22]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[23]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[23]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[24]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[25]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[26]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[27]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[2]
Voltage-gated potassium channel Kv11.1 (KCNH2)	TTQ6VDM	KCNH2_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
• [3] Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
• [4] Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol. 2003 May;63(5):1051-8. doi: 10.1124/mol.63.5.1051.
• [5] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [6] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [7] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [8] 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
• [9] Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
• [10] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [11] The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
• [12] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [13] Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
• [14] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [15] Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
• [16] Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
• [17] 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
• [18] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [19] Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
• [20] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [21] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [22] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [23] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [24] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [25] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [26] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [27] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.